FACTORS ASSOCIATED WITH HYPERTENSION PREVALENCE AND CONTROL AMONG LEBANESE TYPE 2 DIABETIC PATIENTS
DOI:
https://doi.org/10.22159/ijpps.2016v8i10.13298Keywords:
Diabetes Mellitus Type II, Hypertension risk factors, Hypertension prevalence, Blood pressure control, LebanonAbstract
Objective: The objectives of this study were to assess the prevalence of hypertension and the level of blood pressure (BP) control among a cohort of diabetic Lebanese patients on antihypertensive medications, as well as to identify factors associated with hypertension prevalence and uncontrolled BP.
Methods: This cross-sectional retrospective study was conducted in a tertiary health care clinic that is specialized in the management and follow-up of diabetic outpatients.
Results: Among the 700 type 2 diabetes mellitus patient files that were screened529 (75%) were found to have hypertension. Hypertension was more prevalent in women, patients aged ≥65-year-old, and those having a body mass index (BMI) of ≥30 (kg/m2) (p-value<0.05). Among the hypertensive cohort, 465 T2DM were on antihypertensive medications and were included in the hypertension control analysis. Ninety-three patients (20%) attained BP control (SBP<140 and DBP<90 mmHg). Multivariate analyses revealed three factors that were significantly associated with uncontrolled BP control: Age being ≥65 y (adjusted OR = 1.96 (95% CI: 1.07–3.61, p-value<0.05), male gender (adjusted OR = 2.57, 95% CI: 1.41–4.66, p-value<0.05) and uncontrolled HDL (adjusted OR = 1.58, 95% CI: 1.33–2.01, p-value = 0.05).
Conclusion: Hypertension is prevalent among the study patients. However, attainment of BP control was poor among these patients. Therefore, there is a need for studies that determine reasons behind this low BP control rate in order to design interventions aiming at improving the standard of care for these patients.
Downloads
References
Colosia AD, Palencia R, Khan S. Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes Metab Syndr Obes: Targets Ther 2013;6:327-38.
Grossman E, Messerli F. Hypertension and diabetes. Adv Cardiol 2008;45:82-106.
Campbell N, Gilbert R, Leiter L, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension in people with type 2 diabetes: Update on pharmacologic management. Canadian Family Physician 2011;57:997-1002, e347-53.
Song S, Hardisty C. Type 2 diabetes mellitus: a high-risk condition for cardiovascular disease irrespective of the different degrees of obesity. Q J Med 2008;101:875-9.
Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23 Suppl 2:54-64.
Cushman W, Evans G, Byington R, Goff D, Grimm R, Cutler J. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85.
Mancia G, Laurent S, Agabiti-Roseic E, Ambrosionid E, Burniere M, Caulfieldf M, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009;27:2121-58.
Lopez-Jaramillo P, Lopez-Lopez J, Lopez-Lopez C, Rodriguez-Alvarez M. The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetol Metab Syndr 2014;6:31.
Holman R, Paul S, Bethel M, Neil H, Matthews D. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-76.
The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus. N Engl J Med 2008;358:2545-59.
Hanson l, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet 1998;351:1755-62.
UK Prospective diabetes study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-13.
National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians (UK); 2008. Available from: http://www.ncbi.nlm.nih.gov/ books/NBK53885. [Last accessed on 06 May 2016]
American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013;36 Suppl 1:11-66.
Bangalore S, Kumar S, Lobach I, Messerli F. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123:2799-810.
Chahoud J, Mrad J, Semaan A, Asmar R. Prevalence of diabetes mellitus among patients with essential arterial hypertension. J Med Liban 2015;63:74-80.
Costanian C, Benett C, Hawlla N, Assaad C, Sibaii A. Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: Findings from a national population-based study. Diabetes Res Clin Pract 2014;105:408-15.
World Health Organisation. Prevalence of diabetes in the WHO Eastern Mediterranean Region. Available from: Http:// www.who.int/diabetes/facts/world_figures/index2.html. [Last accessed on 06 May 2016]
Tohme RA, Jurjus AR, Estephan A. The prevalence of hypertension and its association with other cardiovascular disease risk factors in a representative sample of the Lebanese population. J Hum Hypertens 2005;19:861–8.
Khan NA, Venkatachalam VV, Alakhali KM, Alavudeen SS, Dhanapal CK, Ansari SMA. Therapeutic management of hypertension and hyperlipidemia in type-2 diabetes mellitus patients in southwestern region of Saudi Arabia: a pharmacist perspective. Asian J Pharm Clin Res 2014;7:241-5.
Andayan TMI, Mohamed Ibrahim MI, Asdie AH. Assessing the impact of complications on the direct medical costs of type 2 diabetes mellitus outpatients. Int J Chem Pharm Res 2010;2:32-5.
Simonson D. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988;11:821-5.
Bell D. Treatment of diabetic hypertension. Diabetes Obes Metab 2009;11:433-44.
Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U. S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28:337-442.
Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens 2010;12:40-6.
Fung V, Huang J, Brand R, Newhouse J, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29:972-84.
Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan Z. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2008;62:338-51.
Cheung B, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 2012;14:160-6.
Basile J. Clinical inertia and blood pressure goal attainment. J Clin Hypertens 2009;11(12, Suppl 1):5–12.
O'Connor P, Sperl-Hillen J, Johnson P, Rush W, Biltz G. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES. editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005. p. 293-308.
Cummings D, Doherty L, Howard G, Howard V, Safford M, Prince V, et al. Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the R Easons for geographic and racial differences in stroke (REGARDS) study. Diabetes Care 2010;33:798-803.
Egan B, Zhao Y, Axon R. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010;303:2043-50.
Barqilla G, listerri J, Prieto M, Alonso-Moreno F, Matarin G, Nafria G, et al. Blood pressure control in a population of hypertensive diabetic patients treated in primary care: PRESCAP-diabetes Study 2010. SEMERGEN-Med Familia 2015;41:13-23.
Abougalambou S, Abougalambou A. A study evaluating prevalence of hypertension and risk factors affecting on blood pressure control among type 2 diabetes patients attending teaching hospital in Malaysia. Diabetol Metab Syndr 2013;7:83-6.
Duggirala M, Cuddihy R, Cuddihy M, Naessens J, Cha S, Mandrekar J, et al. Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005;18:833-8.
Cummings D, Letter A, Howard G, Howard V, Safford M, Prince V, et al. Generic medications and blood pressure control in diabetic hypertensive subjects: results from the R easons for geographic and racial differences in stroke (REGARDS) study. Diabetes Care 2013;36:591-7.
Duggirala MK, Cuddihy RM, Cuddihy MT, Nyman M, Naessens JM, Pankratz VS. Women with diabetes have poorer control of blood pressure than men. Int J Women's Health 2005;14:418-23.
Mubarak F, Froelicher E, Jaddou H, Ajlounia K. Hypertension among 1000 patients with type 2 diabetes attending a national diabetes center in Jordan. Ann Saudi Med 2008;28:346-51.
Serra N, Oliveras A, Bergoñon S, Sans L, Cobos A, MartÃnez P, et al. Factors associated with blood pressure control in diabetic patients treated in nephrology units: PRESDIAB study. Nefrologia 2011;31:313-21.
Lopez-Ruiz A, Sartori-Valinotti J, Yanes L, Iliescu R, Reckelhoff J. Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am J Physiol Heart Circ Physiol 2008;295:466-74.
Miao D, YE P, Xiao E, Gao P, Zhang J, Wu HM. Influence of low high-density lipoprotein cholesterol on arterial stiffening and left ventricular diastolic dysfunction in essential hypertension. J Clin Hypertens 2011;13:710-5.
Basile J, Bloch M. Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease. J Clin Hypertens 2013;15:2-4.
Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia-lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens 2014;27:130-9.
Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood-pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013;15:737-49.
Published
How to Cite
Issue
Section
